After receiving the ethical approval in Tanzania, NeuroSolve obtained the ethical clearance in Zambia too. The ethical clearance certificate will allow to conduct medical research on Neurocysticercosis also in Zambia.

NeuroSolve is a four-year project funded by the European Commission and EDCTP3, started on May 1, 2023. The African Institutions involved are: University of Dar es Salaam (Tanzania), Sokoine University of Agriculture (Tanzania), University of Zambia (Zambia); the European Institutions are: Universiteit Ghent (Belgium) and R-Evolution Worldwide Srl – Impresa Sociale (Italy), that is also the project Coordinator. NeuroSolve is committed to fight taeniasis/Neurocysticercosis (NCC) disease in Sub-Saharan Africa.

Potrebbe essere un'immagine raffigurante testo

Leave a Reply

Your email address will not be published. Required fields are marked *

Explore More

50th anniversary of the WHO declaration of malaria-free Italy

On the 50th anniversary of the WHO declaration of malaria-free Italy, national and international institutions engaged in the fight against malaria meet to discuss the contribution of scientific research to

Read More

OPTIMAL-RSV AFRICA PROPOSAL SUBMITTED TO EDCTP3 TO IMPROVING NEWBORN PROTECTION AGAINTS RESPIRATORY INFECTION IN AFRICA

Respiratory infections remain one of the main causes of illness and death among newborns in sub-Saharan Africa. Respiratory Syncytial Virus (RSV) is a major contributor to severe disease in the

Read More

HANTAAN-VAX-EU-Proposal submitted under the Horizon Europe call for a multiplatform vaccine against Hantaan virus

Hantaan virus (HTNV) is one of the main causes of haemorrhagic fever with renal syndrome (HFRS), a severe disease affecting endemic regions across Asia, with growing concern over its geographical

Read More